Simplifying Global Compliance
FDAnews Device Daily Bulletin
ABBOTT LABS STILL HAS 'CONSIDERABLE' UPSIDE POTENTIAL
Nov. 30, 2005
Banc of America Securities reiterated a "buy" rating on Abbott Laboratories
and lowered the target price to $46 from $49. The research firm said "there
is still much to like" about Abbott, and that shares of the healthcare-products
company have "considerable" upside potential.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing